These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 29979634)

  • 21. Distribution of alpha-galactosidase A in normal human kidney and renal accumulation and distribution of recombinant alpha-galactosidase A in Fabry mice.
    Christensen EI; Zhou Q; Sørensen SS; Rasmussen AK; Jacobsen C; Feldt-Rasmussen U; Nielsen R
    J Am Soc Nephrol; 2007 Mar; 18(3):698-706. PubMed ID: 17287429
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term inhibition of glycosphingolipid accumulation in Fabry model mice by a single systemic injection of AAV1 vector in the neonatal period.
    Ogawa K; Hirai Y; Ishizaki M; Takahashi H; Hanawa H; Fukunaga Y; Shimada T
    Mol Genet Metab; 2009 Mar; 96(3):91-6. PubMed ID: 19091614
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fabry disease - Vascular manifestations.
    Karetova D; Bultas J; Dostalova G; Palecek T; Kovarnik T; Golan L; Linhart A
    Vasa; 2010 May; 39(2):123-31. PubMed ID: 20464667
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The neurological manifestations of Fabry disease. A review].
    Firsov KV; Kotov AS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(9):98-105. PubMed ID: 27735906
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Kidney histologic alterations in α-Galactosidase-deficient mice.
    Valbuena C; Oliveira JP; Carneiro F; Relvas S; Ganhão M; Sá-Miranda MC; Rodrigues LG
    Virchows Arch; 2011 Apr; 458(4):477-86. PubMed ID: 21328014
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neurophysiological, behavioral and morphological abnormalities in the Fabry knockout mice.
    Rodrigues LG; Ferraz MJ; Rodrigues D; Pais-Vieira M; Lima D; Brady RO; Sousa MM; Sá-Miranda MC
    Neurobiol Dis; 2009 Jan; 33(1):48-56. PubMed ID: 18848893
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Fabry disease. Clinical and genetic aspects. Therapeutic perspectives].
    Germain DP
    Rev Med Interne; 2000 Dec; 21(12):1086-103. PubMed ID: 11191676
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A symptomatic Fabry disease mouse model generated by inducing globotriaosylceramide synthesis.
    Taguchi A; Maruyama H; Nameta M; Yamamoto T; Matsuda J; Kulkarni AB; Yoshioka H; Ishii S
    Biochem J; 2013 Dec; 456(3):373-83. PubMed ID: 24094090
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Correction of enzymatic and lysosomal storage defects in Fabry mice by adenovirus-mediated gene transfer.
    Ziegler RJ; Yew NS; Li C; Cherry M; Berthelette P; Romanczuk H; Ioannou YA; Zeidner KM; Desnick RJ; Cheng SH
    Hum Gene Ther; 1999 Jul; 10(10):1667-82. PubMed ID: 10428212
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differences in cleavage of globotriaosylceramide and its derivatives accumulated in organs of young Fabry mice following enzyme replacement therapy.
    Kodama T; Tsukimura T; Kawashima I; Sato A; Sakuraba H; Togawa T
    Mol Genet Metab; 2017; 120(1-2):116-120. PubMed ID: 27756537
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel frameshift mutation in a heterozygous woman with Fabry disease and end-stage renal failure.
    Van Loo A; Vanholder R; Madsen K; Praet M; Kint J; De Paepe A; Messiaen L; Lameire N; Hasholt L; Sørensen SA; Ringoir S
    Am J Nephrol; 1996; 16(4):352-7. PubMed ID: 8739292
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fabry disease: detection of undiagnosed hemodialysis patients and identification of a "renal variant" phenotype.
    Nakao S; Kodama C; Takenaka T; Tanaka A; Yasumoto Y; Yoshida A; Kanzaki T; Enriquez AL; Eng CM; Tanaka H; Tei C; Desnick RJ
    Kidney Int; 2003 Sep; 64(3):801-7. PubMed ID: 12911529
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transgenic mouse expressing human mutant alpha-galactosidase A in an endogenous enzyme deficient background: a biochemical animal model for studying active-site specific chaperone therapy for Fabry disease.
    Ishii S; Yoshioka H; Mannen K; Kulkarni AB; Fan JQ
    Biochim Biophys Acta; 2004 Nov; 1690(3):250-7. PubMed ID: 15511632
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Local and global cerebral blood flow and glucose utilization in the alpha-galactosidase A knockout mouse model of Fabry disease.
    Itoh Y; Esaki T; Cook M; Qasba P; Shimoji K; Alroy J; Brady RO; Sokoloff L; Moore DF
    J Neurochem; 2001 Dec; 79(6):1217-24. PubMed ID: 11752062
    [TBL] [Abstract][Full Text] [Related]  

  • 35. alpha-Galactosidase A deficient mice: a model of Fabry disease.
    Ohshima T; Murray GJ; Swaim WD; Longenecker G; Quirk JM; Cardarelli CO; Sugimoto Y; Pastan I; Gottesman MM; Brady RO; Kulkarni AB
    Proc Natl Acad Sci U S A; 1997 Mar; 94(6):2540-4. PubMed ID: 9122231
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The kidney in Fabry's disease.
    Pisani A; Visciano B; Imbriaco M; Di Nuzzi A; Mancini A; Marchetiello C; Riccio E
    Clin Genet; 2014 Oct; 86(4):301-9. PubMed ID: 24645664
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lysosomal glycosphingolipid catabolism by acid ceramidase: formation of glycosphingoid bases during deficiency of glycosidases.
    Ferraz MJ; Marques AR; Appelman MD; Verhoek M; Strijland A; Mirzaian M; Scheij S; Ouairy CM; Lahav D; Wisse P; Overkleeft HS; Boot RG; Aerts JM
    FEBS Lett; 2016 Mar; 590(6):716-25. PubMed ID: 26898341
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term enzyme correction and lipid reduction in multiple organs of primary and secondary transplanted Fabry mice receiving transduced bone marrow cells.
    Takenaka T; Murray GJ; Qin G; Quirk JM; Ohshima T; Qasba P; Clark K; Kulkarni AB; Brady RO; Medin JA
    Proc Natl Acad Sci U S A; 2000 Jun; 97(13):7515-20. PubMed ID: 10840053
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Detection of preclinical left ventricular dysfunction in Fabry disease: the contribution of tissue Doppler.
    Fiuza M; Avó LB; Oliveira EI; Gonçalves S; Lopes MG
    Rev Port Cardiol; 2006 Jun; 25(6):613-37. PubMed ID: 17019980
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence of Fabry disease in young patients with cryptogenic ischemic stroke.
    Dubuc V; Moore DF; Gioia LC; Saposnik G; Selchen D; Lanthier S
    J Stroke Cerebrovasc Dis; 2013 Nov; 22(8):1288-92. PubMed ID: 23168217
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.